Seoul Economic Daily EnglishDoubao · 实盘不做把握 8/10不做原因:证据不足
北京时间·🕒 发布 13:31:01(首尔 14:31)·⟳ 抓取 13:43:46 +12m45s·⚡ 决策 09-14 13:47:23 +3m37s·43.3 天前
柳韩洋行在WCLC披露口服HER2药物YH42946早期临床设计，但未公布可重估的疗效数据
这是一次正向但极早期的临床进度更新：没有人体疗效读数、没有监管批准、没有交易金额或近期收入，2期尚在2027年初；柳韩洋行股价盘中也未出现正向重估，因此不具备可交易edge。
📄 原文Seoul Economic Daily English↗ 原文
Yuhan Speeds Up Development of Oral HER2 Cancer Drug YH42946
Seoul Economic Daily Skip to main content Seoul Economic Daily Seoul Economic Daily KST Seoul Economic Daily Korea's Le…
不做 柳韩洋行（Yuhan Corporation）（000100.KS）
本次仅披露早期1/2期设计和入组进度，无疗效/安全性阳性读数、无监管或商业化进展；脑转移效果仍来自动物实验，且2期要到2027年初，短线基本面edge不足。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
YH42946的口服给药和脑转移潜力具备长期期权价值，但WCLC披露停留在1/2期设计和入组进度层面。真正的估值催化应等待2026年底安全性与早期疗效数据，而非现在仅凭会议海报做多。
消息传播链
- 会前预览已提到柳韩洋行将在WCLC介绍YH42946临床现状，说明演讲日程并非意外，但当时没有具体临床结果。
- 较早韩文报道称柳韩洋行在WCLC公开YH42946的首次人体1/2期研究设计，并计划年底得出早期结果。
- 医学媒体补充1期Part 1登记53人、23人持续治疗，但仍未披露ORR等疗效指标。
- 英文媒体转述公司说法，强调口服、脑转移动物数据和2027年初2期计划；未引用公司英文IR公告原文。
- 2026-09-14 14:44 KST市场反应yfinance非一手柳韩洋行盘中约79,000韩元、较前收79,400韩元下跌0.5%，未见消息驱动的正向重定价。市场反应:000100.KS盘中约-0.5%。
关键理由
- 本次新增信息主要是时间表确认：年底取得1期结果、2027年初进入2期，并未披露能证明临床优势的ORR、PFS或关键安全性数据。
- 柳韩洋行是成熟大型药企，单一首次人体早期项目在未读出阳性数据前，难以相对其现有Lazertinib royalty等业务产生显著短期市值弹性。
主要风险
- 若海报全文实际披露了新闻未转述的强阳性人体反应或脑转移数据，可能触发即时重估。
- 2026年底1期数据若超预期，YH42946可能成为“后Lazertinib”管线期权，届时需要重新评估。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-09-14 · 影响 weakens
同日报道均表述为试验设计、入组现状和未来时间表，未发现可支撑估值重估的人体疗效数据。
检索:YH42946 WCLC 2026 ORR PFS safety results Phase 1 原文 ↗ - 做多前查反向 · 来源 stock_quote · 日期 2026-09-14 · 影响 none
消息传播时柳韩洋行盘中约-0.5%，近20个交易日累计约-3.76%，未出现正向抢跑或事件驱动跳涨。
检索:유한양행 YH42946 9월14일 주가 반응
先例如何影响了这次决策
对本次决策的影响:先例不足与事件本身早期属性共同导致不设交易、不设定止盈止损；等待年底1期读数后再研究。
方向:未取得可用于统计的、同市场同机制且首发锚点可靠的早期临床设计披露先例。
涨幅量级:没有高相似对齐先例校准涨幅；本次又缺少疗效数据，不能用其他阳性临床读出案例的涨幅外推。
形态:无法从可靠先例确认会议海报是否会高开低走；当前盘中小幅下跌更支持市场未把该消息视为重大surprise。
工具执行结果 · 成功 7 · 降级 1 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 26 ms
{"result": "search_processed_events:agent query=`j ints bio yh42946 license her2 egfr exon 20 | yuhan yh42946 oral her2 phase 1/2 wclc 2026 | 유한양행 yh42946 her2 경구용 항암제 wclc`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；按当前事件继续正常研判。"} - fetch_decision_experience 成功 stock_tools HTTP · 72 ms
{ - web_search 成功 doubao_search · 2,122 ms
豆包搜索结果（原始查询:Yuhan YH42946 WCLC 2026 Phase 1 HER2 J INTS Bio market reaction；API SearchType:web） - stock_quote 降级 stock_tools HTTP · 3,936 ms
{ - direct_instrument_candidates 成功 stock_tools HTTP · 19 ms
{ - web_search 成功 doubao_search · 1,653 ms
豆包搜索结果（原始查询:유한양행 WCLC 임상 디자인 발표 당일 주가 반응 YH42946 9월14일；API SearchType:web） - web_search 成功 doubao_search · 1,094 ms
豆包搜索结果（原始查询:site:yuhan.co.kr YH42946 WCLC 2026 HER2 oral；API SearchType:web） - web_search 成功 doubao_search · 1,876 ms
豆包搜索结果（原始查询:J INTS BIO private company KRX listed 제이인츠바이오 상장；API SearchType:web）
原文全文
展开原文 · 4,592 字
Yuhan Speeds Up Development of Oral HER2 Cancer Drug YH42946 - Seoul Economic Daily
Skip to main content
Seoul Economic Daily
Seoul Economic Daily
KST
Seoul Economic Daily
Korea's Leading Business News Since 1960
한국어
Menu
Saved Articles
Newsletters
AI KEY
Settings
|
Summary
|
Save
A
A
A
Lim Sun-min, professor of medical oncology at Yonsei Cancer Center, presents Phase 1/2 trial results for Yuhan's oral HER2-targeted therapy "YH42946" at the 2026 World Conference on Lung Cancer (WCLC) held at COEX in Seoul. Photo courtesy of Yuhan Corp.
Yuhan Corporation is accelerating clinical development of YH42946, an oral HER2-targeting cancer drug, aiming to secure early Phase 1 results by the end of this year and begin a Phase 2 trial early next year.
The company said on the 14th that it disclosed the design and current status of the Phase 1/2 trial of YH42946 at the 2026 World Conference on Lung Cancer (WCLC) held at COEX in Seoul.
YH42946 is an oral targeted therapy aimed at HER2, a protein that drives cancer cell growth. Yuhan has been developing the drug since licensing the technology from J INTS BIO in 2023. Its target patient population covers not only HER2 mutations, amplification and overexpression but also cancers carrying EGFR exon 20 insertion mutations.
The drug's potential against brain metastases is drawing particular attention. Patients with HER2 or EGFR exon 20 mutations frequently develop brain metastases, but some existing treatments require intravenous administration or carry limitations such as toxicity. YH42946 is being developed as an oral drug, and animal studies confirmed its effect on tumors that had spread to the brain.
The ongoing Phase 1/2 trial enrolls patients with advanced or metastatic solid tumors carrying HER2 or EGFR exon 20 mutations. The Phase 1 portion escalates doses in stages to assess safety, the appropriate dose and early anti-tumor activity.
Yuhan expects to obtain Phase 1 results on safety and early anti-tumor activity by the end of this year. Based on those findings, the company plans to select two dose levels and begin a Phase 2 trial in early 2027 to determine the optimal dose. It then intends to expand development to other types of solid tumors with HER2 abnormalities.
"YH42946 is a new treatment option for patients with solid tumors carrying HER2 abnormalities and EGFR exon 20 insertion mutations — an oral drug that can also be expected to show effect on brain metastatic lesions," said Kim Yeul-hong, president and head of R&D at Yuhan. "We will move quickly to establish the recommended dose and advance follow-up development."
#
Yuhan
#
YH42946
#
HER2
#
LungCancer
#
WCLC2026
#
TargetedTherapy
#
KoreaPharma
Original reporting by
Park Hong-yong
for Seoul Economic Daily.
AI-translated from Korean. Quotes from foreign sources are based on Korean-language reports and may not reflect exact original wording.
Translated by AI on
Sep 14, 2026
View Korean original
↗
Translation Policy
Watch · Seoul Economic Daily
More →
2:20
KB Securities Sees Samsung Back at No.1, SK Hynix at No.3 Next Year | September 14 2026 | Securities Daily
2:20
Most Read This Week
1
-
5
‹
›
1
JBL Launches Xtreme 5 Bluetooth Speaker With Stronger Bass
2
Hyundai, POSCO Break Ground on $5.8 Billion U.S. Steel Mill
3
China Pumps 300 Billion Yuan Into Eight Financial Firms
4
Korea to Offer 20,000 Homes at 1,000 Won a Day for Young Adults
5
Samsung, SK hynix Memory Stockpiles Fall Below 10 Days
← Back to Home
AI KEY
Preview
↗
Korean Corporate Intelligence Hub
KOSPI · KOSDAQ · 12 sectors
A live, cap-weighted view of every KOSPI and KOSDAQ sector, with same-day Korean reporting distilled by company — built for foreign investors, correspondents and analysts who need to scan Korea before the next session.
Click to explore AI KEY
→
Open AI KEY in full screen
↗
Korea Company Atlas
Preview
↗
Market Ontology · The Feedback Loop
KFTC 2025 · 92 groups · 121,954 articles
An English ontology of the Korean market — how companies, the media, the government and the National Assembly move each other in a loop. Korea's named controlling persons and designated business groups are a mechanism, not a risk to be priced blind.
Click to explore the atlas
→
Open Atlas in full screen
↗
SIGNAL
Now live
↗
English Edition · Capital Markets
M&A · IPO · PE · Fund Flows
SIGNAL English Edition is live — Korea's deal desk reporting in English. M&A, IPOs, private equity and fund flows, covered daily for global institutional investors. Browse free; subscriber-only scoops at the 50% intro rate.
Click to explore SIGNAL
→
Open SIGNAL in full screen
↗
Skip to main content
Seoul Economic Daily
Seoul Economic Daily
KST
Seoul Economic Daily
Korea's Leading Business News Since 1960
한국어
Menu
Saved Articles
Newsletters
AI KEY
Settings
|
Summary
|
Save
A
A
A
Lim Sun-min, professor of medical oncology at Yonsei Cancer Center, presents Phase 1/2 trial results for Yuhan's oral HER2-targeted therapy "YH42946" at the 2026 World Conference on Lung Cancer (WCLC) held at COEX in Seoul. Photo courtesy of Yuhan Corp.
Yuhan Corporation is accelerating clinical development of YH42946, an oral HER2-targeting cancer drug, aiming to secure early Phase 1 results by the end of this year and begin a Phase 2 trial early next year.
The company said on the 14th that it disclosed the design and current status of the Phase 1/2 trial of YH42946 at the 2026 World Conference on Lung Cancer (WCLC) held at COEX in Seoul.
YH42946 is an oral targeted therapy aimed at HER2, a protein that drives cancer cell growth. Yuhan has been developing the drug since licensing the technology from J INTS BIO in 2023. Its target patient population covers not only HER2 mutations, amplification and overexpression but also cancers carrying EGFR exon 20 insertion mutations.
The drug's potential against brain metastases is drawing particular attention. Patients with HER2 or EGFR exon 20 mutations frequently develop brain metastases, but some existing treatments require intravenous administration or carry limitations such as toxicity. YH42946 is being developed as an oral drug, and animal studies confirmed its effect on tumors that had spread to the brain.
The ongoing Phase 1/2 trial enrolls patients with advanced or metastatic solid tumors carrying HER2 or EGFR exon 20 mutations. The Phase 1 portion escalates doses in stages to assess safety, the appropriate dose and early anti-tumor activity.
Yuhan expects to obtain Phase 1 results on safety and early anti-tumor activity by the end of this year. Based on those findings, the company plans to select two dose levels and begin a Phase 2 trial in early 2027 to determine the optimal dose. It then intends to expand development to other types of solid tumors with HER2 abnormalities.
"YH42946 is a new treatment option for patients with solid tumors carrying HER2 abnormalities and EGFR exon 20 insertion mutations — an oral drug that can also be expected to show effect on brain metastatic lesions," said Kim Yeul-hong, president and head of R&D at Yuhan. "We will move quickly to establish the recommended dose and advance follow-up development."
#
Yuhan
#
YH42946
#
HER2
#
LungCancer
#
WCLC2026
#
TargetedTherapy
#
KoreaPharma
Original reporting by
Park Hong-yong
for Seoul Economic Daily.
AI-translated from Korean. Quotes from foreign sources are based on Korean-language reports and may not reflect exact original wording.
Translated by AI on
Sep 14, 2026
View Korean original
↗
Translation Policy
Watch · Seoul Economic Daily
More →
2:20
KB Securities Sees Samsung Back at No.1, SK Hynix at No.3 Next Year | September 14 2026 | Securities Daily
2:20
Most Read This Week
1
-
5
‹
›
1
JBL Launches Xtreme 5 Bluetooth Speaker With Stronger Bass
2
Hyundai, POSCO Break Ground on $5.8 Billion U.S. Steel Mill
3
China Pumps 300 Billion Yuan Into Eight Financial Firms
4
Korea to Offer 20,000 Homes at 1,000 Won a Day for Young Adults
5
Samsung, SK hynix Memory Stockpiles Fall Below 10 Days
← Back to Home
AI KEY
Preview
↗
Korean Corporate Intelligence Hub
KOSPI · KOSDAQ · 12 sectors
A live, cap-weighted view of every KOSPI and KOSDAQ sector, with same-day Korean reporting distilled by company — built for foreign investors, correspondents and analysts who need to scan Korea before the next session.
Click to explore AI KEY
→
Open AI KEY in full screen
↗
Korea Company Atlas
Preview
↗
Market Ontology · The Feedback Loop
KFTC 2025 · 92 groups · 121,954 articles
An English ontology of the Korean market — how companies, the media, the government and the National Assembly move each other in a loop. Korea's named controlling persons and designated business groups are a mechanism, not a risk to be priced blind.
Click to explore the atlas
→
Open Atlas in full screen
↗
SIGNAL
Now live
↗
English Edition · Capital Markets
M&A · IPO · PE · Fund Flows
SIGNAL English Edition is live — Korea's deal desk reporting in English. M&A, IPOs, private equity and fund flows, covered daily for global institutional investors. Browse free; subscriber-only scoops at the 50% intro rate.
Click to explore SIGNAL
→
Open SIGNAL in full screen
↗
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。